Table 2 Surgery details and complications

From: Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial

Surgical Details

n = 43

ICT Therapy, n (%)

 Nivolumab

14 (33)

 Nivolumab  +  Bevacizumab

16 (37)

 Nivolumab  +  Ipilimumab

13 (30)

Surgery Type, n (%)

 CN

39 (91)

 Metastasectomy

4 (9)

CN details, n (%)*

 Open

23 (59)

 Laparoscopic

16 (41)

 Included thrombectomy

9 (23)

 Included RPLND

18 (46)

Median EBL, mL (IQR)

200 (100-500)

Intraoperative complications

0

90-day postoperative complications

6 (14)

Historical CN complication rates7

12–57%

  1. *Percent of cytoreductive nephrectomy patients (n = 39).
  2. CN, cytoreductive nephrectomy, RPLND, retroperitoneal lymph node dissection, EBL estimated blood loss, IQR interquartile range.
Back to article page